Qnasl
NDC Package 59310-210-08

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Qnasl is a medication used to treat seasonal and year-round allergy symptoms such as stuffy/runny nose, itching, and sneezing. Marketed by Teva Respiratory, Llc, this product is identified by NDC 59310-210 and is authorized under FDA application NDA202813.

Identification & Billing

NDC Package Code
59310-210-08
Package Description
1 INHALER in 1 CARTON / 50 AEROSOL, METERED in 1 INHALER
Product Code
59310-210
11-Digit Billing Format
59310021008

Clinical Specifications

Proprietary Name
Qnasl
Dosage Form
-
Usage Information
This medication is used to treat seasonal and year-round allergy symptoms such as stuffy/runny nose, itching, and sneezing. It may also reduce other symptoms of seasonal allergies such as red, itchy, and watery eyes. This medication belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) in the nasal passages.

Regulatory & Marketing

Labeler Name
Teva Respiratory, Llc
FDA Application #
NDA202813
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-13-2012
End Marketing Date
02-12-2020
Listing Expiration
02-12-2020
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (59310-210). Click a package code to view its specific billing and regulatory data.

59310-210-12
1 INHALER in 1 CARTON / 120 AEROSOL, METERED in 1 INHALER
59310-210-13
1 INHALER in 1 CARTON / 50 AEROSOL, METERED in 1 INHALER
59310-210-14
1 INHALER in 1 CARTON / 120 AEROSOL, METERED in 1 INHALER

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 59310-210-08 identifies a specific commercial package of 1 inhaler in 1 carton / 50 aerosol, metered in 1 inhaler of Qnasl, labeled by Teva Respiratory, Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Teva Respiratory, Llc on April 13, 2012. The current certification is valid through February 12, 2020.

What are the primary indications for this medication?

This medication is used to treat seasonal and year-round allergy symptoms such as stuffy/runny nose, itching, and sneezing. It may also reduce other symptoms of seasonal allergies such as red, itchy, and watery eyes. This medication belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) in the nasal passages.

How is this Teva Respiratory, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 59310021008. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
59310-210-08
11-Digit CMS (5-4-2)
59310-0210-08

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.